Castle Biosciences (NASDAQ:CSTL) Insider Sells $108,767.04 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 3,288 shares of the business’s stock in a transaction dated Monday, October 26th. The shares were sold at an average price of $33.08, for a total value of $108,767.04. Following the completion of the transaction, the insider directly owned 45,431 shares of the company’s stock, valued at approximately $1,502,857.48. This trade represents a 6.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Performance

Shares of CSTL traded up $2.17 during mid-day trading on Wednesday, reaching $36.68. The company had a trading volume of 431,159 shares, compared to its average volume of 391,490. The stock has a market capitalization of $1.12 billion, a P/E ratio of -55.58 and a beta of 0.94. Castle Biosciences, Inc. has a 52-week low of $17.72 and a 52-week high of $44.28. The stock has a 50 day moving average of $33.86 and a two-hundred day moving average of $28.71. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.34. The firm had revenue of $99.86 million for the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. On average, analysts expect that Castle Biosciences, Inc. will post -1.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. BTIG Research raised their price objective on shares of Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Weiss Ratings upgraded shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Robert W. Baird set a $36.00 price target on shares of Castle Biosciences in a report on Friday, July 31st. Finally, Wall Street Zen lowered shares of Castle Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Castle Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Hedge Funds Weigh In On Castle Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the company. NFSG Corp acquired a new stake in shares of Castle Biosciences in the third quarter worth approximately $36,000. Global Retirement Partners LLC acquired a new position in Castle Biosciences in the 2nd quarter valued at $26,000. Quantbot Technologies LP acquired a new position in Castle Biosciences in the 2nd quarter valued at $62,000. State of Wyoming acquired a new position in Castle Biosciences in the 2nd quarter valued at $117,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Castle Biosciences by 15.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,574 shares of the company’s stock valued at $194,000 after purchasing an additional 747 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company focuses on conditions in which additional biological information can complement traditional pathology and clinical assessment.

Its portfolio includes DecisionDx-Melanoma, which helps evaluate the risk of metastatic recurrence in patients with cutaneous melanoma; DecisionDx-SCC, which assesses metastatic risk in cutaneous squamous cell carcinoma; and DecisionDx-UM, a test for determining metastatic risk in uveal melanoma.